Century Therapeutics Inc.
Organization details
- Legal name
- Century Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2836 — Biological Products, (No Diagnostic Substances)
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Philadelphia
- Headquarters state / province
- Pennsylvania
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- IPSC
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001850119
- EIN
- 84-2040295
- Wikidata ID
- Q107519701
Board of directors
-
Alessandro Riva · DirectorSince 2023
-
Brent Pfeiffenberger · Director · President and CEOSince 2023
-
Cynthia M. Butitta · DirectorSince 2023
-
Daphne Quimi · DirectorSince 2023
-
Han Myung Lee · DirectorSince 2025
- Since 2023
-
Joseph Truitt · DirectorSince 2026
-
Kimberly Blackwell · DirectorSince 2023
-
Martin Patrick Murphy · DirectorSince 2025
-
Rizzuto Carlo · DirectorSince 2023
- Since 2023
Chief executives
Outstanding · grade A+
Out of 100, from shareholder return, dividends, growth and acquisitions.
Partial: only 20% of the scoring weight is on file.
- Revenue growth 20%
- 100
175.9% a year in revenue
20% of the scoring weight is on file. Figures cover December 2022 – December 2025.
Director election results
Annual meeting of June 11, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
84.5%
-
99.9%
Board connections
9 of this board's directors also sit on 21 other boards. 18 are in the same sector.
-
LENZ Therapeutics Inc. Same sectorvia Joseph Jimenez and Rizzuto Carlo
-
Amylyx Pharmaceuticals Inc. Same sectorvia Daphne Quimi
- via Cynthia M. Butitta
-
BeOne Medicines Ltd. Same sectorvia Alessandro Riva
-
Bicycle Therapeutics plc Same sectorvia Alessandro Riva
-
BioMarin Pharmaceutical Inc. Same sectorvia Timothy P. Walbert
-
Butterfly Network Inc. Same sectorvia Brent Pfeiffenberger
-
Corbus Pharmaceuticals Holdings Inc. Same sectorvia Brent Pfeiffenberger
- via Joseph Jimenez
-
Kardigan Inc. Same sectorvia Timothy P. Walbert
-
Larimar Therapeutics Inc. Same sectorvia Joseph Truitt
-
Latigo Biotherapeutics Inc. Same sectorvia Timothy P. Walbert
-
Mirum Pharmaceuticals Inc. Same sectorvia Timothy P. Walbert
-
Monte Rosa Therapeutics Inc. Same sectorvia Kimberly Blackwell
-
Odyssey Therapeutics Inc. Same sectorvia Timothy P. Walbert
-
Olema Pharmaceuticals Inc. Same sectorvia Cynthia M. Butitta
- via Joseph Jimenez
-
Sagimet Biosciences Inc. Same sectorvia Timothy P. Walbert
- via Joseph Jimenez
-
UroGen Pharma Ltd. Same sectorvia Cynthia M. Butitta
-
Zentalis Pharmaceuticals Inc. Same sectorvia Kimberly Blackwell
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $97,011
- 3 purchases by 2 insiders
- Sold, last 12 months
- $86,293
- 20 sales by 4 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 3, 2026 | Carr Douglas Officer (SVP Finance & Operations) | Open-market sale | −266 | $1.52 | $404 |
| Sep 14, 2026 | Carr Douglas Officer (SVP Finance & Operations) | Open-market sale | −1,658 | $1.93 | $3,200 |
| Sep 14, 2026 | Russotti Gregory Officer (See Remarks) | Open-market sale | −2,587 | $1.93 | $4,993 |
| Sep 11, 2026 | Brent Pfeiffenberger Director, Officer (President and CEO) | Shares withheld for tax | −13,850 | $1.94 | $26,869 |
| Sep 8, 2026 | Carr Douglas Officer (SVP Finance & Operations) | Open-market sale | −254 | $2.05 | $521 |
| Sep 8, 2026 | Russotti Gregory Officer (See Remarks) | Open-market sale | −534 | $2.05 | $1,095 |
| Sep 4, 2026 | Brent Pfeiffenberger Director, Officer (President and CEO) | Shares withheld for tax | −463 | $2.11 | $977 |
| Aug 14, 2026 | Brent Pfeiffenberger Director, Officer (President and CEO) | Shares withheld for tax | −31,172 | $1.92 | $59,850 |
| Aug 3, 2026 | Carr Douglas Officer (SVP Finance & Operations) | Open-market sale | −275 | $1.98 | $545 |
| Jun 12, 2026 | Russotti Gregory Officer (See Remarks) | Open-market sale | −2,584 | $2.23 | $5,762 |
| Jun 12, 2026 | Carr Douglas Officer (SVP Finance & Operations) | Open-market sale | −1,654 | $2.23 | $3,688 |
| Jun 11, 2026 | Brent Pfeiffenberger Director, Officer (President and CEO) | Shares withheld for tax | −13,849 | $2.24 | $31,022 |
| Jun 11, 2026 | Cowan Chad Officer (Chief Scientific Officer) | Shares withheld for tax | −358 | $2.24 | $802 |
| Jun 8, 2026 | Russotti Gregory Officer (See Remarks) | Open-market sale | −524 | $2.11 | $1,106 |
| Jun 8, 2026 | Carr Douglas Officer (SVP Finance & Operations) | Open-market sale | −249 | $2.11 | $525 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Century Therapeutics Inc.
Who is the CEO of Century Therapeutics Inc.?
Brent Pfeiffenberger has been Century Therapeutics Inc.'s President and CEO since December 2023.
How many directors are on Century Therapeutics Inc.'s board?
Century Therapeutics Inc.'s board has 11 directors: Alessandro Riva, Brent Pfeiffenberger, Cynthia M. Butitta, Daphne Quimi, Han Myung Lee, Joseph Jimenez, Joseph Truitt, Kimberly Blackwell, Martin Patrick Murphy, Rizzuto Carlo and 1 other.
Are Century Therapeutics Inc. insiders buying or selling shares?
Over the last 12 months, Century Therapeutics Inc. insiders bought $97,011 of shares in 3 purchases and sold $86,293 of shares in 20 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="century-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.